2025-08-19T15:26:16-07:00 2024-12-31 815169849 Attolero 9508 Devonshire Drive Huntersville NC 28078 990 2024-01-01 471810644 KCNQ2 Cure Alliance KCNQ 3038879532 3700 Quebec St Unit 100-118 Denver CO 80207 Jim Johnson President 2025-08-19 true true Robert Bales P02160108 7046412949 2024 2025-03-06 01:10:19Z X Scotty Sims 458475 false X www.kcnq2cure.org X 2015 CO KCNQ2 Cure Alliance is a non-profit organization dedicated to raising research funds for KCNQ2 epileptic encephalopathy, a rare and catastrophic form of epilepsy. By offering research grants for KCNQ2 research with a novel approach, we can move researchers and the medical community forward to find better treatments and a cure while assisting afflicted individuals and their families. 5 4 0 4 0 290960 387797 7767 0 70678 0 298727 458475 4752 15117 0 0 0 6773 129639 71117 134391 86234 164336 372241 881712 1234962 11319 881712 1223643 KCNQ2 Cure Alliance is a non-profit organization dedicated to raising research funds for KCNQ2 epileptic encephalopathy, a rare and catastrophic form of epilepsy. By offering research grants for KCNQ2 research with a novel approach, we can move researchers and the medical community forward to find better treatments and a cure while assisting afflicted individuals and their families. false false 55398 15117 Funding of patient-derived DNA and clinical data to identify modifiers of the KCNQ2 phenotype. Identifying these genetic and environmental modifiers will improve our capability to make an accurate prognosis for individual patients, can help to define current best treatment strategies and will help to identify novel disease pathways that can be targeted to improve outcome in the general KCNQ2-RD population. 55398 true true false false false false false false false false true true false false true false false false false false false false false false false false false true false false false false false false false false false false false false false false false false false false false true 5 0 true 0 false false false false false false false 0 false false false false false false false X 5 4 false false false false false false false true true false false true true true true false true true false false CO X X KCNQ2 Cure Alliance 3038879532 3700 Quebec St Denver CO 80207 X Jim Johnson President 5.00 0.00 X X 0 0 0 Sara James Vice President 5.00 0.00 X X 0 0 0 Caroline Loewy Treasurer 5.00 0.00 X X 0 0 0 Matthew Fox Director 0.00 0.00 X 0 0 0 Colin Sanford Secretary 5.00 0.00 X X 0 0 0 0 false false false 0 387797 387797 0 70678 70678 0 0 0 0 0 0 0 0 458475 70678 15117 15117 0 0 0 0 0 0 0 0 0 11853 11853 0 4025 4025 0 0 0 0 159 159 98 98 5056 4768 288 0 0 5175 2260 2915 0 0 0 0 244 244 2071 2071 Program Manager 22437 22437 Contractor & other Prof. 12639 11576 1063 Operational Expenses 2946 1482 1464 Patient Support programs 1500 1500 2914 1583 1331 86234 55398 24063 6773 881085 521022 0 0 0 0 0 0 0 0 1565 213 627 1352 0 712588 0 0 0 881712 1234962 9776 1543 0 11319 X 881712 1223643 881712 1223643 881712 1234962 372241 -30310 X false false false X 175590 177319 115903 290960 387797 1147569 0 0 175590 177319 115903 290960 387797 1147569 0 1147569 70678 70678 0 0 1218247 0.94200 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 938 213 725 627 627 1352 712588 Credit Card 1543 1543 true SynGAP Research Fund PO Box 104191 Pasadena CA 91189 831200789 15117 0 KCNQ2 research 1 0 Grantmaker's Description of How Grants are Used A written scientific progress report regarding the project must be submitted to the Foundation six (6) months from the effective date for the release of funding described in the grant agreement. A final scientific progress report and financial report detailing all expenditures for the life of the grant will be due no later than sixty (60) days following the expiration or termination of the grant, as described in the Foundation?s policy statement on research support. In addition, annual financial reports must be submitted to the Foundation to substantiate expenses for the applicable period. Form 990, Part VI, Section B, Line 11b The return is furnished to the foundation's treasurer for review and submitted to the Executive Board (Executive Director, President, Vice President, Treasurer, and Secretary) for approval before being submitted for filing. Form 990, Part VI, Section B, Line 12c Any interests that could give rise to a conflict must be disclosed to the Board. However, no contract or transaction between the Foundation and one or more of its members, directors, or officers, or any other foundation, partnership, association, or other organization in which one or more of this Foundation?s directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for such reason, or solely because the member, director, or officer is present or participates in the meeting of the Board of Directors which authorizes the contract or transaction, or solely because his or their votes are counted for such purpose if: The material facts as to the relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors, and the Board of Directors in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors are less than a quorum; The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors, and the contract or transaction is specifically approved in good faith by a vote of such directors; or The contract or transaction is fair as to the Foundation as of the time it is authorized, approved, or ratified by the Board of Directors. Form 990, Part VI, Section B, Line 15a The Compensation Committee shall consist of the Vice President and Treasurer. They will review the contract rate and other benefits of the Executive Director. As part of this review, the Compensation Committee will make a recommendation to the Board of Directors regarding the Executive Director?s contract rate and other benefits to be paid for the upcoming year. This shall be done on an annual basis. The vote of a majority of the directors entitled to vote at a meeting at which a quorum is present shall determine the rate and other benefits of the Executive Director. This shall be done on an annual basis, no later than sixty (60) days after the anniversary date of the Executive Director?s date of hire. Form 990, Part VI, Section C, Line 19 The foundation made its governing documents, conflict of interest policy, and financial statements available to the public on its website and Guidestar upon request.